pharmacists and physicians in Omnicare-serviced nursing homes to "educate" these audiences on
the importance of the switching program and on how to switch patients from other ACE
inhibitors (including, by this time, mostly Monopril) to Accupril.
commencement of mass switching to Accupril to educate pharmacists on how to make the
switches. Meetings were held with Omnicare staff where Pfizer's marketing staff and Omnicare
senior management together informed Omnicare's front line pharmacists and pharmacy
supervisors that the switches were not only going to be beneficial to patients in Omnicare-
serviced long-term care facilities, but would save payors money.
Pfizer also made marketing agents available to Omnicare pharmacists who needed
subsequent technical assistance to switch patients from other ACE inhibitors to Accupril.
authorizing blanket switches to Accupril.
Pfizer's actions in furtherance of this conspiracy
Making false statements 10 Omnicare fi'onl line pharmacy personnel as to the reason for the switching. Pfizer made false representations to Omnicare pharmacy staft: through materials prepared uniquely for Omnicare staff, through "kickoff' and other meetings designed to maximize the wholesale switching, and through making themselves available for technical consultations. These false representations included:
That the switch to Accupril was financially advantageous to the government and private insurers, when this was almost never the case.
That Accupril was clinically the most appropriate ACE inhibitor, when frequently
this, too, was not the case.
Making false statements to physicians as to the reasons for the switching. Pfizer made its
marketing personnel available at Omnicare-serviced nursing homes to work with